+384.6%
NVDA vs MRNA
+34.8%
+349.8%
-36.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +5.4% | -5.4% | -0.2% |
| 7D | -5.1% | -1.1% | -4.0% | -5.1% |
| 30D | -2.5% | +126.1% | -128.6% | -7.2% |
| 3M | +6.7% | +190.0% | -183.4% | -2.8% |
| 6M | +17.6% | +157.2% | -139.6% | +8.5% |
| YTD | +17.3% | +388.2% | -370.9% | -1.8% |
| 1Y | +23.5% | +467.0% | -443.5% | -0.1% |
| 3Y | +384.6% | +36.1% | +348.5% | +352.4% |
| All | +384.6% | +34.8% | +349.8% | +352.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling